A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Recruiting now · Phase 1
Conditions studied: Haematologic Neoplasms
In brief
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Key facts
- Study ID
- NCT07064122
- Run by
- AstraZeneca
- People needed
- 72
- Starts
- 2025-11-03
- Expected to finish
- 2028-10-20
- Last updated by the study team
- 2026-03-02
Who can join
Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Manchester, United Kingdom (enrolling)
- Research Site — Tampa, Florida, United States (enrolling)
- Research Site — Houston, Texas, United States (enrolling)
- Research Site — Heidelberg, Australia (enrolling)
- Research Site — Melbourne, Australia (enrolling)
- Research Site — Shinagawa-ku, Japan (enrolling)
- Research Site — Yoshida-gun, Japan (enrolling)
- Research Site — Madrid, Spain (enrolling)
- Research Site — Pamplona, Spain (enrolling)
- Research Site — Salamanca, Spain (enrolling)
- Research Site — Taipei, Taiwan (enrolling)
- Research Site — London, United Kingdom (enrolling)
- Research Site — London, United Kingdom (enrolling)
- Research Site — Barcelona, Spain (enrolling)
- Research Site — Madrid, Spain (enrolling)
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Miami, Florida, United States
- Research Site — Valencia, Spain
- Research Site — Kaohsiung City, Taiwan
- Research Site — Tainan, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.